How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,171 results for

Pheochromocytoma

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

2. Pheochromocytoma in Children With MEN Type 2B

Pheochromocytoma in Children With MEN Type 2B We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Pheochromocytoma in Children and Adolescents With Multiple Endocrine Neoplasia Type 2B | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic Search Account Menu Menu Navbar Search Filter Mobile Microsite Search Term Close search filter search input (...) Article Navigation Close mobile search navigation Article navigation January 2019 Article Navigation Pheochromocytoma in Children and Adolescents With Multiple Endocrine Neoplasia Type 2B Angeliki Makri Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, Maryland Correspondence and Reprint Requests: Angeliki Makri, MD, MSc, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National

Full Text available with Trip Pro

2019 Pediatric Endocrine Society

3. Adrenocorticotropic Hormone Secreting Pheochromocytoma Underlying Glucocorticoid Induced Pheochromocytoma Crisis (PubMed)

Adrenocorticotropic Hormone Secreting Pheochromocytoma Underlying Glucocorticoid Induced Pheochromocytoma Crisis Pheochromocytomas are hormone secreting tumors of the medulla of the adrenal glands found in 0.1-0.5% of patients with hypertension. The vast majority of pheochromocytomas secrete catecholamines, but they have been occasionally shown to also secrete interleukins, calcitonin, testosterone, and in rare cases adrenocorticotropic hormone. Pheochromocytoma crisis is a life threatening (...) following administration of glucocorticoids as preparation for intravenous contrast administration. Throughout his admission, the patient demonstrated both signs of Cushing's syndrome and high catecholamine levels. Following stabilization of vital parameters and serum electrolytes, the adrenal mass was resected surgically and was found to harbor an adrenocorticotropic hormone secreting pheochromocytoma. This is the first documented case of adrenocorticotropic hormone secreting pheochromocytoma

Full Text available with Trip Pro

2018 Case reports in endocrinology

4. Severe Cushing Syndrome Due to an ACTH-Producing Pheochromocytoma: A Case Presentation and Review of the Literature (PubMed)

Severe Cushing Syndrome Due to an ACTH-Producing Pheochromocytoma: A Case Presentation and Review of the Literature Adrenocorticotropic hormone (ACTH)-dependent Cushing syndrome is rarely caused by a pheochromocytoma. We present a case of a 46-year-old woman who developed severe hypertension, hypokalemia, and typical Cushingoid features. Investigations revealed extremely high metanephrine, cortisol, and ACTH levels. Imaging showed a 3.8-cm left adrenal mass. Preoperative control of hypertension (...) and hypokalemia was very challenging. The patient was cured after surgical removal of the adrenal mass. We followed this by a review of the literature using the databases Google Scholar and PubMed. A total of 58 cases have been reported to date. In summary, ACTH-producing pheochromocytoma is a rare condition that poses a clinical challenge in the perioperative period. It is important that physicians be aware of such a condition because early recognition and treatment are crucial to decrease morbidity

Full Text available with Trip Pro

2018 Journal of the Endocrine Society

5. Pathogenicity and Penetrance of Germline SDHA Variants in Pheochromocytoma and Paraganglioma (PPGL) (PubMed)

Pathogenicity and Penetrance of Germline SDHA Variants in Pheochromocytoma and Paraganglioma (PPGL) Germline SDHA mutations are reported in a minority of pheochromocytoma/paraganglioma (PPGL) cases but are associated with an increased risk of malignancy, leading some to advocate cascade genetic testing and surveillance screening of "at-risk" first-degree relatives. However, such approaches rely on accurate estimates of variant pathogenicity and disease penetrance, which may have been subject

Full Text available with Trip Pro

2018 Journal of the Endocrine Society

6. A Rare Location and Presentation of Pheochromocytoma (PubMed)

A Rare Location and Presentation of Pheochromocytoma Background: Pheochromocytomas typically are diagnosed in the adrenal gland and from the sympathetic nervous system. Bladder pheochromocytoma is a rare location for this tumor. Case Presentation: We describe a 67-year-old Afro Caribbean woman referred to our hospital for an asymptomatic bladder tumor. Preliminary transurethral resection revealed bladder pheochromocytoma. After a comprehensive endocrine evaluation, we performed a robot-assisted (...) laparoscopic partial cystectomy with ureteral reimplantation. Conclusion: We present a rare case of bladder pheochromocytoma treated effectively with minimally invasive techniques. When confronted with a solid bladder mass, apart from the more common urothelial malignancies, a differential diagnosis of bladder pheochromocytoma should also be considered.

Full Text available with Trip Pro

2018 Journal of endourology case reports

7. Educational Case: Pheochromocytoma (PubMed)

Educational Case: Pheochromocytoma The following fictional case is intended as a learning tool within the Pathology Competencies for Medical Education (PCME), a set of national standards for teaching pathology. These are divided into three basic competencies: Disease Mechanisms and Processes, Organ System Pathology, and Diagnostic Medicine and Therapeutic Pathology. For additional information, and a full list of learning objectives for all three competencies, see http://journals.sagepub.com/doi

Full Text available with Trip Pro

2018 Academic pathology

8. Ectopic Thyroid Tissue in the Adrenal Gland Mimicking a Pheochromocytoma (PubMed)

Ectopic Thyroid Tissue in the Adrenal Gland Mimicking a Pheochromocytoma Ectopic thyroid tissue in the adrenal gland (ETTAG) usually presents as a well-circumscribed cystic mass on a CT scan. However, the MRI features of ETTAG are incompletely understood. We report a case of ectopic thyroid tissue in the adrenal gland, which demonstrates findings similar to those of a pheochromocytoma on the MRI.

Full Text available with Trip Pro

2017 Journal of endourology case reports

9. Case Report of a Prolactinoma in a Patient With a Novel MAX Mutation and Bilateral Pheochromocytomas (PubMed)

Case Report of a Prolactinoma in a Patient With a Novel MAX Mutation and Bilateral Pheochromocytomas Pheochromocytomas are neuroendocrine tumors that can arise sporadically or be inherited as a familial disease, and they may occur in isolation or as part of a multitumor syndrome. Familial disease typically presents in younger patients with a higher risk of multifocality. Recently, the tumor suppressor MYC-associated factor X (MAX) gene has been implicated as a cause of familial isolated (...) pheochromocytoma and paraganglioma. We describe a patient with a pituitary prolactinoma and bilateral pheochromocytomas who tested positive for a germline MAX mutation. Interestingly, the patient also had mild primary hyperparathyroidism that resolved upon resection of the pheochromocytomas despite the absence of parathyroid hormone staining in the tumors. To our knowledge, this case is the first report of prolactinoma in a patient with a MAX mutation, which suggests the possibility of germline MAX mutations

Full Text available with Trip Pro

2017 Journal of the Endocrine Society

10. Max Schottelius: Pioneer in Pheochromocytoma (PubMed)

Max Schottelius: Pioneer in Pheochromocytoma First descriptions of diseases attract tremendous interest because they reveal scientific insight even in retrospect. Max Schottelius, the pathologist contributing the first histological description of pheochromocytoma, remains anonymous. We reviewed the description by Schottelius and weighed the report in modern context. Schottelius described the classical diagnostic elements of pheochromocytoma, including the brown appearance after exposure (...) to chromate-containing Mueller's fixative. This color change, known as chromaffin reaction, results from oxidation of catecholamines and is reflected in the name pheochromocytoma, meaning dusky-colored chromate-positive tumor. Thus Schottelius performed the first known histochemical contribution to diagnosis, which is today standard with immunohistochemistry for chromogranin.

Full Text available with Trip Pro

2017 Journal of the Endocrine Society

11. External beam radiation therapy for advanced/unresectable malignant paraganglioma and pheochromocytoma (PubMed)

External beam radiation therapy for advanced/unresectable malignant paraganglioma and pheochromocytoma To evaluate the role of external beam radiation therapy (EBRT) for treatment of malignant paraganglioma (PGL) and pheochromocytoma (PCC).A retrospective review was performed of all patients with malignant PGL/PCC treated with EBRT at our institution between 1973 and 2015. Local control (LC) per treated lesion and overall survival were estimated using the Kaplan-Meier method. Toxicities were

Full Text available with Trip Pro

2017 Advances in radiation oncology

12. Extracorporeal life support (ECLS) for pheochromocytoma-induced cardiogenic shock: a systematic review

Extracorporeal life support (ECLS) for pheochromocytoma-induced cardiogenic shock: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

13. Laboratory Endocrine Testing Guidelines: Pheochromocytoma

Laboratory Endocrine Testing Guidelines: Pheochromocytoma LABORATORY ENDOCRINE TESTING: PHEOCHROMOCYTOMA Clinical Practice Guideline | January 2008 These recommendations are systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances. They should be used as an adjunct to sound clinical decision making. OBJECTIVE Alberta clinicians optimize laboratory testing for investigation of suspected pheochrmocytoma (...) and refer to an endocrinologist as soon as possible TARGET POPULATION Patients with typical symptoms, hypertension refractory to multiple drug regimens, accelerated hypertension, known familial syndromes, paradoxic hypertensive responses to antihypertensives, hypertensive episodes during surgical procedures, incidental findings of an adrenal tumor EXCLUSIONS None RECOMMENDATIONS ? Refer patients suspected of having pheochromocytoma to an endocrinologist as soon as possible ? Request a 24 hour urine

2014 Toward Optimized Practice

14. Positive impact of genetic test on the management and outcome of patients with paraganglioma and/or pheochromocytoma. (PubMed)

Positive impact of genetic test on the management and outcome of patients with paraganglioma and/or pheochromocytoma. Pheochromocytomas and paragangliomas (PPGLs) are characterized by a strong genetic component, with up to 40% of patients carrying a germline mutation in a PPGL susceptibility gene. International guidelines recommend that genetic screening be proposed to all patients with PPGL.Our objective was to evaluate how a positive genetic test impacts the management and outcome of patients

2019 Journal of Clinical Endocrinology and Metabolism

15. Pheochromocytoma and paraganglioma-an update on diagnosis, evaluation, and management. (PubMed)

Pheochromocytoma and paraganglioma-an update on diagnosis, evaluation, and management. Pheochromocytomas and paragangliomas (PPGLs) generally grouped together are rare catecholamine-secreting endocrine tumors. Symptoms of catecholamine excess are non-specific and therefore a high index of suspicion in children with sustained hypertension, family history of endocrine tumors, or features of syndromes associated with PPGLs leads to a timely diagnosis and treatment. Free metanephrines in the plasma

2019 Pediatric Nephrology

16. Combined epidural-general anesthesia was associated with lower risk of postoperative complications in patients undergoing open abdominal surgery for pheochromocytoma: A retrospective cohort study. (PubMed)

Combined epidural-general anesthesia was associated with lower risk of postoperative complications in patients undergoing open abdominal surgery for pheochromocytoma: A retrospective cohort study. Current evidences show that regional anesthesia is associated with decreased risk of complications after major surgery. However, the effects of combined regional-general anesthesia remain controversial. The purpose of our study was to analyze the impact of anesthesia (combined epidural-general (...) anesthesia vs. general anesthesia) on the risk of postoperative complications in patients undergoing open surgery for pheochromocytoma.This was a retrospective cohort study. 146 patients who underwent open surgery for pheochromocytoma (100 received combined epidural-general anesthesia and 46 received general anesthesia) in Peking University First Hospital from January 1, 2002 to December 31, 2015 were enrolled. The primary outcome was the occurrence of postoperative complications during hospital stay

Full Text available with Trip Pro

2018 PLoS ONE

17. Renal infarction associated with extra-adrenal pheochromocytoma. (PubMed)

Renal infarction associated with extra-adrenal pheochromocytoma. Pheochromocytomas have been described to be associated with renal infarction in a few sporadic cases. The underlying pathophysiologic mechanisms are catecholoamine-induced vasospasm and direct compression or invasion of the tumor on renal artery or its branches. However, renal infarction caused by extra-adrenal pheochromocytoma is rarely reported. We describe an unusual case of benign extra-adrenal pheochromocytoma complicated

2019 Urology

18. Impact of 123 I-MIBG scintigraphy on clinical decision making in pheochromocytoma and paraganglioma. (PubMed)

Impact of 123 I-MIBG scintigraphy on clinical decision making in pheochromocytoma and paraganglioma. Cross sectional imaging with computed tomography (CT) or magnetic resonance imaging (MRI) is regarded as a first-choice modality for tumor localization in patients with pheochromocytoma and paraganglioma (PPGL). 123I-labeled metaiodobenzylguanidine (123I-MIBG) is widely used for functional imaging but the added diagnostic value is controversial.To establish the virtual impact of adding 123I-MIBG

2019 Journal of Clinical Endocrinology and Metabolism

19. Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-Prono study): an ENS@T retrospective study. (PubMed)

Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-Prono study): an ENS@T retrospective study. Malignant pheochromocytoma and paraganglioma (MPP) are characterized by prognostic heterogeneity. Our objective was to look for prognostic parameters of overall survival in MPP patients.Retrospective multicentric study of MPP characterized by a neck-thoraco-abdomino-pelvic CT or MRI at the time of malignancy diagnosis in European centers between 1998 and 2010.We included 169 patients from (...) 18 European centers. Main characteristics of MPP patients were: primary pheochromocytoma in 53% of patients, tumor or hormone-related symptoms in 57% or 58% of cases, positive plasma or urine hormones in 81% of patients, identification of a mutation in SDHB in 42 % of cases. Metastatic sites included the bone (64%), lymph node (40%), lung (29%) and liver (26%); mean time between initial and malignancy diagnosis was 43 months (0-614). Median follow-up was 68 months and median survival 6.7 years

2019 Journal of Clinical Endocrinology and Metabolism

20. Type A Aortic Dissection Complicated by Pheochromocytoma. (PubMed)

Type A Aortic Dissection Complicated by Pheochromocytoma. This report presents a case of aortic dissection as the patient's initial presentation of an undiagnosed pheochromocytoma. A 36-year-old man presented with substernal chest pressure and abdominal pain. Computed tomography revealed type A aortic dissection with a 3.6-cm left adrenal mass. Elevated catecholamine levels were diagnostic of pheochromocytoma. Type A aortic dissection caused by uncontrolled hypertension secondary (...) to pheochromocytoma is a rare entity. This can complicate surgical planning. Although this situation is rare, it is important to consider pheochromocytoma in the differential diagnosis of uncontrolled hypertension in the setting of type A aortic dissection.Copyright © 2019 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

2019 Annals of Thoracic Surgery

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>